Jan 14, 2026
In the rapidly shifting landscape of modern healthcare, the traditional boundaries of the hospital ward are dissolving. The emergence of Vital Sign Monitors (VSM) and External Remote Patient Monitoring (RPM) devices represents one of the most significant shifts in clinical practice since the invention of the stetho...
Read More...
Jan 13, 2026
Insilico Medicine Doses First Patient in Phase IIa Trial of Garutadustat for Inflammatory Bowel Disease Insilico Medicine has dosed the first patient in its Phase IIa clinical trial of Garutadustat, an AI-designed small-molecule therapy being developed for Inflammatory Bowel Disease (IBD), specifically ulcerativ...
Read More...
Jan 12, 2026
Summary Chronic hepatitis B continues to pose a major global health challenge, affecting millions globally. ~5 million prevalent CHB cases across the 7MM in 2024. No complete cure exists yet, but advances in antivirals and novel modalities are reshaping therapeutic outcomes and hope for a functional cure. ...
Read More...
Jan 09, 2026
Vitiligo represents a significant yet underrecognized health burden globally. Vitiligo, a chronic autoimmune depigmenting disorder affecting 11.7 million individuals across the leading markets in 2024, is undergoing a seismic shift in therapeutic approaches. The condition typically emerges during the second and thi...
Read More...
Jan 08, 2026
Gore Gained FDA Approval for First Deep Venous Stent Indicated for the IVC and Iliofemoral Veins On January 06, 2026, W. L. Gore & Associates’ medical business (Gore) announced that it had received FDA approval for the GORE® VIABAHN® FORTEGRA Venous Stent, formerly known as the GORE® VIAFORT Vascular S...
Read More...
Jan 07, 2026
From Smart Monitoring to Life-Saving Therapy: Why Every Modern Household Needs This Health Toolkit The shift of healthcare from sterile clinic walls to the comfort of your living room is one of the most powerful trends of the 21st century. Driven by an aging population, rising chronic disease rates, and rapid te...
Read More...
Jan 06, 2026
Zenas BioPharma Announces Successful Phase 3 INDIGO Study of Obexelimab in IgG4-RD Zenas BioPharma has announced positive top-line results from its pivotal Phase 3 INDIGO clinical trial evaluating obexelimab for the treatment of IgG4-Related Disease (IgG4-RD). IgG4-RD is a rare, systemic, chronic fibroinflammato...
Read More...
Jan 05, 2026
The FDA has approved YARTEMLEA (narsoplimab-wuug), marking a watershed moment in hematopoietic stem cell transplantation (HSCT) medicine. Omeros Corporation's therapeutic advance represents the first and only FDA-approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA...
Read More...
Jan 02, 2026
Delta-like Ligand 3 (DLL3) is rapidly establishing a position as one of the promising targets in the treatment of aggressive Neuroendocrine Cancers (NECs), including Small Cell Lung Cancer (SCLC), Neuroendocrine Prostate Cancer (NEPC), and Large-Cell Neuroendocrine Carcinoma (LCNEC), where existing treatments deliv...
Read More...
Jan 01, 2026
FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy On December 23, 2025, Edwards Lifesciences announced that its SAPIEN M3 mitral valve replacement system, the first transcatheter therapy using a transseptal approach, received approval from the...
Read More...